Use of Convalescent Plasma Therapy among Hospitalized Coronavirus Disease 2019 (COVID-19) Patients: A Single-Center Experience

摘要: ABSTRACT: COVID-19 Disease has strained our healthcare system. Convalescent plasma been used to treat emerging infectious diseases - Influenza A/B, SARS-CoV, Ebola virus and now SARS-CoV 2. OBJECTIVE: This study aims determine the outcome clinical course of COVID-19 patients who received convalescent transfusion at Cardinal Santos Medical Center. METHODS: is a retrospective cohort analytical 75 plasma. RESULTS: Median time from admission CP was 3 days. Majority additional therapies including dexamethasone (100%); Remdesivir (95%); antibiotics (100%), tocilizumab (65%); hemoperfusion (88%) or combination these. Among survivors, median LOS 15 days while non-survivors have 6 One patient (1.33%) had mild reaction. Four (5.33%) developed DVT despite anti-coagulation. There improvement in inflammatory markers (LDH pvalue 0.04, CRP 0.00, Ferritin 0.0001). pulmonary parameters increase mean PaO2, SaO2, PFR; decrease FiO2 RR post-treatment. 14 for group vs 11 non-CP group. Mortality rate among 25.33% 26.67%. mortality did not reach statistical significance. CONCLUSIONS: no significant difference length hospital stay given controls. might role status.